Uncategorized
Imprimis reports 508% increase in revenue in third quarter
Imprimis Pharmaceuticals reported $2.7 million in total revenue in the third quarter, a 508% increase from $0.4 million reported in the same quarter of 2014, according to a press release. Sales for Tri-Moxi and Tri-Moxi-Vanc compounded injectable formulations were reported at $594,000 in the third quarter. Sales for combination topical eye drop formulations were reported at $263,000.